From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Future Medicinal Chemistry

• Publication date

  2014-06-19

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4155/fmc.14.30PMID 24941871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.

  2014cited by this paper
• Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

  2013cited by this paper
• Chemical probes for drug-resistance assessment by binding competition (RABC): oseltamivir susceptibility evaluation.

  2013cited by this paper
• Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.

  2013cited by this paper
• Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.

  2013cited by this paper
• Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors

  2013cited by this paper
• Synthesis of 1,4-triazole linked zanamivir dimers as highly potent inhibitors of influenza A and B

  2013cited by this paper
• Novel 3,4-disubstituted-Neu5Ac2en derivatives as probes to investigate flexibility of the influenza virus sialidase 150-loop.

  2013cited by this paper
• Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity

  2013cited by this paper
• Enhanced anti-influenza agents conjugated with anti-inflammatory activity.

  2012cited by this paper
• Recent Advances in Neuraminidase Inhibitor Development as Anti‐influenza Drugs

  2012cited by this paper
• Antivirals targeting influenza A virus.

  2012cited by this paper
• Development of oseltamivir phosphonate congeners as anti-influenza agents.

  2012cited by this paper
• Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility.

  2012cited by this paper
• Oseltamivir

  2012cited by this paper
• Polymer-attached zanamivir inhibits synergistically both early and late stages of influenza virus infection

  2012cited by this paper
• A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity.

  2011cited by this paper
• Interactions of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.

  2011cited by this paper
• Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.

  2011cited by this paper
• Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza

  2011cited by this paper
• Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.

  2011cited by this paper
• Mechanism of 150-cavity formation in influenza neuraminidase

  2011cited by this paper
• Peramivir: another tool for influenza treatment?

  2011cited by this paper
• Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes.

  2011cited by this paper
• Biotin-, fluorescein- and 'clickable' conjugates of phospha-oseltamivir as probes for the influenza virus which utilize selective binding to the neuraminidase.

  2011cited by this paper
• Structures of influenza A proteins and insights into antiviral drug targets

  2010cited by this paper
• Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.

  2010cited by this paper
• Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.

  2010cited by this paper
• Influenza vaccines for the future.

  2010cited by this paper
• Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza

  2010cited by this paper
• Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration

  2010cited by this paper
• Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase

  2010cited by this paper
• Bifunctional Polymeric Inhibitors of Human Influenza A Viruses

  2010cited by this paper
• Clinical Pharmacokinetics of Laninamivir, a Novel Long‐Acting Neuraminidase Inhibitor, After Single and Multiple Inhaled Doses of Its Prodrug, CS‐8958, in Healthy Male Volunteers

  2010cited by this paper
• Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.

  2010cited by this paper
• Novel insights into proteolytic cleavage of influenza virus hemagglutinin

  2010cited by this paper
• Differential receptor binding affinities of influenza hemagglutinins on glycan arrays.

  2010cited by this paper
• Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza

  2010cited by this paper
• Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles.

  2010cited by this paper
• Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol.

  2009cited by this paper
• Design and synthesis of immobilized Tamiflu analog on resin for affinity chromatography

  2009cited by this paper
• Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.

  2009cited by this paper
• The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.

  2009cited by this paper
• Synthetic and natural immunomodulators acting as interferon inducers.

  2009cited by this paper
• Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.

  2009cited by this paper
• CS-8958, a Prodrug of the Novel Neuraminidase Inhibitor R-125489, Demonstrates a Favorable Long-Retention Profile in the Mouse Respiratory Tract

  2009cited by this paper
• Confronting the next influenza pandemic with anti‐inflammatory and immunomodulatory agents: why they are needed and how they might work

  2009cited by this paper
• Efficient Synthesis of Highly Active Phospha‐Isosteres of the Influenza Neuraminidase Inhibitor Oseltamivir

  2009cited by this paper
• A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase.

  2009cited by this paper
• Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.

  2009cited by this paper
• Global transmission of oseltamivir-resistant influenza.

  2009cited by this paper
• Characterizing Loop Dynamics and Ligand Recognition in Human- and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations

  2009cited by this paper
• Galactose-conjugates of the oseltamivir pharmacophore--new tools for the characterization of influenza virus neuraminidases.

  2009cited by this paper
• The evolution of influenza resistance and treatment.

  2009cited by this paper
• Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.

  2008cited by this paper
• Phosphate coordination and movement of DNA in the Tn5 synaptic complex: role of the (R)YREK motif

  2008cited by this paper
• Correlates of protection: novel generations of influenza vaccines.

  2008cited by this paper
• Structural basis for the function and inhibition of an influenza virus proton channel

  2008cited by this paper
• CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity

  2008cited by this paper
• Structure and mechanism of the M2 proton channel of influenza A virus

  2008cited by this paper
• Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

  2008cited by this paper
• Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants

  2008cited by this paper
• Scientific barriers to developing vaccines against avian influenza viruses

  2007cited by this paper
• The war against influenza: discovery and development of sialidase inhibitors

  2007cited by this paper
• The war against influenza: discovery and development of sialidase inhibitors.

  2007cited by this paper
• Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).

  2007cited by this paper
• Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection

  2007cited by this paper
• Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity.

  2007cited by this paper
• Structure and functions of influenza virus neuraminidase.

  2007cited by this paper
• Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design.

  2007cited by this paper
• Vaccines for seasonal and pandemic influenza.

  2006cited by this paper
• The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design

  2006cited by this paper
• Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.

  2005cited by this paper
• Noncovalent binding between guanidinium and anionic groups: focus on biological- and synthetic-based arginine/guanidinium interactions with phosph[on]ate and sulf[on]ate residues.

  2005cited by this paper
• One‐Bead–One‐Inhibitor–One‐Substrate Screening of Neuraminidase Activity

  2005cited by this paper
• Neuraminidase inhibitors for influenza.

  2005cited by this paper
• Potent and Long-Acting Dimeric Inhibitors of Influenza Virus Neuraminidase Are Effective at a Once-Weekly Dosing Regimen

  2004cited by this paper
• Photoinactivation of viruses

  2004cited by this paper
• Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.

  2004cited by this paper
• Photodynamic therapy: a new antimicrobial approach to infectious disease?

  2004cited by this paper
• Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.

  2003cited by this paper
• Combination anti‐inflammatory and antiviral therapy of influenza in a cotton rat model

  2003cited by this paper
• Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.

  2002cited by this paper
• Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.

  2002cited by this paper
• Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza

  2002cited by this paper
• Zanamivir

  2002cited by this paper
• Clinical Pharmacokinetics of Salmeterol

  2002cited by this paper
• Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir.

  2002cited by this paper
• Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir

  2002cited by this paper
• The cluster glycoside effect.

  2002cited by this paper
• Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm.

  2002cited by this paper
• Oseltamivir: a review of its use in influenza.

  2001cited by this paper
• Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.

  2001cited by this paper
• Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor.

  2000cited by this paper
• Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.

  2000cited by this paper
• Resistance of influenza viruses to neuraminidase inhibitors--a review.

  2000cited by this paper
• Intestinal Peptide Transport Systems and Oral Drug Availability

  1999cited by this paper
• Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers

  1999cited by this paper
• Zanamivir

  1999cited by this paper
• Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain.

  1999cited by this paper

• Mechanism of action of substituted peramivir phosphonate derivatives as potent oseltamivir-resistant influenza A virus using molecular docking, molecular dynamics simulations, and free energies calculations

  2025cites this paper
• Chemoenzymatic synthesis of sialyl-α2,3-lactoside-functionalized BSA conjugate inhibits influenza infection.

  2024cites this paper
• Preparation of a thioxoimidazolidin-linked sialoside BSA conjugate for the inhibition of influenza virus.

  2024cites this paper
• Synthetic pentatrideca-valent triazolylsialoside inhibits influenza virus hemagglutinin/neuraminidase and aggregates virion particles.

  2023cites this paper
• Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus.

  2022cites this paper
• Sialidase Inhibitors with Different Mechanisms

  2022cites this paper
• Oseltamivir modified bovine serum albumin inhibits neuraminidase activity and accumulates virion particles to disturb influenza virus replication.

  2022cites this paper
• Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design

  2021cites this paper
• Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection.

  2020cites this paper
• Amide-sialoside protein conjugates as neomucin bioshields prevent influenza virus infection.

  2020cites this paper
• Synthesis of glycocluster-containing conjugates for a vaccine against cholera.

  2019cites this paper
• A Review: Influenza and its Therapeutic Approaches

  2019cites this paper
• Multivalent Effect in Glycosidase Inhibition: The End of the Beginning.

  2019cites this paper
• Peramivir conjugates as orally available agents against influenza H275Y mutant.

  2018cites this paper
• A comparison of RSV and influenza in vitro kinetic parameters reveals differences in infecting time

  2018cites this paper
• A Sulfonozanamivir Analogue Has Potent Anti‐influenza Virus Activity

  2018cites this paper
• Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.

  2018cites this paper
• Inhibition of sialidase activity as a therapeutic approach

  2018cites this paper
• 2D-SAR, Topomer CoMFA and molecular docking studies on avian influenza neuraminidase inhibitors

  2018cites this paper
• Multivalent zanamivir-bovine serum albumin conjugate as a potent influenza neuraminidase inhibitor

  2017cites this paper
• The design, synthesis and biological evaluation of carbohydrate-based probes of proteins

  2017cites this paper
• The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses

  2017cites this paper
• Glycans in Infectious Diseases. A Molecular Recognition Perspective.

  2017cites this paper
• Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives.

  2017cites this paper
• A sialosyl sulfonate as a potent inhibitor of influenza virus replication.

  2017cites this paper
• Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity

  2016cites this paper
• Polyvalent Effect Enhances Anti-influenza Virus Activity

  2016cites this paper
• Synthesis of multivalent difluorinated zanamivir analogs as potent antiviral inhibitors

  2016cites this paper
• Development of Influenza Virus Sialidase Inhibitors

  2016cites this paper
• A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action

  2016cites this paper
• Multivalent S-sialoside protein conjugates block influenza hemagglutinin and neuraminidase.

  2016cites this paper
• Recent progress in designing inhibitors that target the drug‐resistant M2 proton channels from the influenza A viruses

  2015cites this paper